Idenix Pharma (IDIX) Updates on Three Developments; FDA Hold on IDX184 Removed
Tweet Send to a Friend
Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX) announced the following updates for three clinical development programs:DX184, a liver-targeted HCV nucleotide prodrug
This article: 322 words
-->
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This article: 322 words
-->
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
